Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Mem Inst Oswaldo Cruz ; 114: e190062, 2019.
Article in English | MEDLINE | ID: mdl-31389521

ABSTRACT

BACKGROUND: Formation of schistosomal granulomata surrounding the ova can result in schistosomiasis-associated liver fibrosis (SSLF). The current standard of treatment is praziquantel (PZQ), which cannot effectively reverse SSLF. The role of the cannabinoid (CB) receptor family in liver fibrosis has recently been highlighted. OBJECTIVES: This study aimed to assess the therapeutic effect of CB1 receptor antagonism in reversing SSLF in a murine model of Schistosoma mansoni infection. METHODS: One hundred male Swiss albino mice were divided equally into five groups: healthy uninfected control (group I), infected control (group II), PZQ treated (group III), rimonabant (RIM) (SR141716, a CB1 receptor antagonist)-treated (group IV) and group V was treated with combined PZQ and RIM. Liver sections were obtained for histopathological examination, alpha-1 smooth muscle actin (α-SMA) immunostaining and assessment of CB1 receptor expression using real-time polymerase chain reaction (RT-PCR). FINDINGS: The most effective reduction in fibrotic marker levels and granuloma load was achieved by combined treatment with PZQ+RIM (group V): CB1 receptor expression (H = 26.612, p < 0.001), number of α-SMA-positive cells (F = 57.086, p < 0.001), % hepatic portal fibrosis (F = 42.849, p < 0.001) and number of granulomata (F = 69.088, p < 0.001). MAIN CONCLUSIONS: Combining PZQ with CB1 receptor antagonists yielded the best results in reversing SSLF. To our knowledge, this is the first study to test this regimen in S. mansoni infection.


Subject(s)
Liver Cirrhosis/drug therapy , Liver Cirrhosis/parasitology , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Rimonabant/pharmacology , Schistosomiasis/drug therapy , Actins/analysis , Animals , Anthelmintics/pharmacology , Cannabinoid Receptor Antagonists/pharmacology , Drug Therapy, Combination , Granuloma/parasitology , Granuloma/pathology , Immunohistochemistry , Liver Cirrhosis/pathology , Male , Mice , Myofibroblasts/parasitology , Myofibroblasts/pathology , Praziquantel/pharmacology , Reproducibility of Results , Schistosomiasis/pathology , Treatment Outcome
2.
Parasit Vectors ; 11(1): 72, 2018 01 30.
Article in English | MEDLINE | ID: mdl-29382361

ABSTRACT

BACKGROUND: Cardiac fibrosis is a consequence of chronic chagasic cardiomyopathy (CCC). In other cardiovascular diseases, the protagonist role of fibroblasts in cardiac fibrosis is well established. However, the role of cardiac fibroblasts (CFs) in fibrosis during the CCC is not clear. Here, our aim was to investigate the effect of Trypanosoma cruzi, the etiological agent of Chagas disease on CFs activation. METHODS: Cardiac fibroblasts were purified from primary cultures of mouse embryo cardiac cells. After two passages, cells were infected with T. cruzi (Y strain) and analyzed at different times for determination of infectivity, activation and production of extracellular matrix components (fibronectin, laminin and collagen IV) by immunofluorescence and western blot. RESULTS: At second passage, cultures were enriched in CFs (95% of fibroblasts and 5% of cardiomyocytes), as revealed by presence of alpha-smooth muscle actin (α-SMA) and discoidin domain receptor 2 (DDR2) and absence of sarcomeric tropomyosin (ST) protein expression. Trypanosoma cruzi infection induced fibroblast-myofibroblast transition, with increased expression of α-SMA after 6 and 24 h post-infection (hpi). Fibronectin was increased at 6, 24 and 48 hpi, laminin was increased at 6 and 24 hpi and collagen IV was increased at 6 hpi. CONCLUSIONS: Our results showed that T. cruzi activates CFs, inducing activation and exacerbates ECM production. Furthermore, our data raise the possibility of the involvement of CFs in heart fibrosis during Chagas disease.


Subject(s)
Extracellular Matrix Proteins/genetics , Fibroblasts/parasitology , Myofibroblasts/parasitology , Trypanosoma cruzi/physiology , Animals , Blotting, Western , Cells, Cultured , Chagas Cardiomyopathy/parasitology , Chagas Cardiomyopathy/physiopathology , Collagen/genetics , Fibroblasts/physiology , Fibronectins/genetics , Fluorescent Antibody Technique , Laminin/genetics , Mice , Myofibroblasts/physiology
SELECTION OF CITATIONS
SEARCH DETAIL